论文部分内容阅读
目的 探讨肾上腺源性雄激素与前列腺癌 (PCa)的关系。 方法 1998年 3月～ 1999年 7月 ,采用雄激素全阻断方法治疗 18例B2 期以上PCa ,并与 2 3例单纯睾丸切除治疗的晚期PCa比较 ,雄激素全阻断法采用睾丸切除加缓退瘤或酮康唑。 结果 雄激素全阻断治疗组可迅速使患者血清睾酮、PSA降低和前列腺体积缩小 ,与单纯睾丸切除组比较 ,血PSA降低和前列腺体积缩小5 0 %的时间差别有显著性意义 (P <0 .0 1)。雄激素全阻断治疗组骨转移灶缓解率为 80 % ,1年有效率为 10 0 % ,而单纯睾丸切除治疗组骨转移灶缓解率为 33.3% ,1年有效率为 82 .2 % ,二组骨转移灶缓解率及 1年有效率相比 ,差别均有显著性意义 (P <0 0 1,P <0 0 5 )。 结论 肾上腺源性雄激素与前列腺癌的进展有密切关系 ,雄激素全阻断治疗可延缓PCa的进展并可提高疗效。
Objective To investigate the relationship between adrenogenic androgens and prostate cancer (PCa). Methods From March 1998 to July 1999, 18 cases of PCa at stage B2 and above were treated with androgen blockade. Compared with 23 cases of advanced PCa treated with simple orchidectomy, androgen blockade plus orchidectomy Retinopathy or ketoconazole. Results In the androgen blockade group, serum testosterone, PSA and prostate volume decreased rapidly. Compared with the simple orchiectomy group, the difference of serum PSA and prostate volume reduction was significant (P <0 .0 1). In the androgen blockade group, the remission rate of bone metastases was 80% and the 1-year effective rate was 100%. The remission rate of bone metastases in the orchidectomy group was 33.3% and the one-year effective rate was 82.2% There was significant difference between the two groups in the rate of bone metastases and the 1-year effective rate (P <0.01, P <0.05). Conclusion Adrenogenic androgen is closely related to the progress of prostate cancer. Androgen blockade can delay the progression of PCa and improve the curative effect.